Abstract
Depression, the most prevalent psychiatric disorder, has a lifelong risk of 20% and is related to high rates of death among the patients. Thus, this study aims to conduct a systematic review of changes in executive functions of adult patients diagnosed with depression. We found 1381 articles; however, only 28 were selected and recovered. The inclusion criteria was the assessment of executive functions with at least one neuropsychological test, and articles that evaluated primarily adult individuals with depression, without comparison to other psychiatric disorders. Although most of the studies (25 out of 28 analyzed) have shown deficits in some executive subcomponents, these findings are not conclusive because they used different parameters of assessment. Moreover, many variables were not controlled, such as the different subtypes of the disorder, the high level of severity, comorbidity and the use of drugs. Most studies showed different deficits in executive functions in depressed patients, but further longitudinal studies are needed in order to confirm these findings.
Keywords: Cognitive impairment, depression, drugs, executive functions, neuropsychological assessment, psychiatric disorders.
CNS & Neurological Disorders - Drug Targets
Title:Executive Function Impairments in Patients with Depression
Volume: 13 Issue: 6
Author(s): Mariana R.P. Alves, Tetsuya Yamamoto, Oscar Arias-Carrion, Nuno B.F. Rocha, Antonio E. Nardi, Sergio Machado and Adriana Cardoso
Affiliation:
Keywords: Cognitive impairment, depression, drugs, executive functions, neuropsychological assessment, psychiatric disorders.
Abstract: Depression, the most prevalent psychiatric disorder, has a lifelong risk of 20% and is related to high rates of death among the patients. Thus, this study aims to conduct a systematic review of changes in executive functions of adult patients diagnosed with depression. We found 1381 articles; however, only 28 were selected and recovered. The inclusion criteria was the assessment of executive functions with at least one neuropsychological test, and articles that evaluated primarily adult individuals with depression, without comparison to other psychiatric disorders. Although most of the studies (25 out of 28 analyzed) have shown deficits in some executive subcomponents, these findings are not conclusive because they used different parameters of assessment. Moreover, many variables were not controlled, such as the different subtypes of the disorder, the high level of severity, comorbidity and the use of drugs. Most studies showed different deficits in executive functions in depressed patients, but further longitudinal studies are needed in order to confirm these findings.
Export Options
About this article
Cite this article as:
Alves R.P. Mariana, Yamamoto Tetsuya, Arias-Carrion Oscar, Rocha B.F. Nuno, Nardi E. Antonio, Machado Sergio and Cardoso Adriana, Executive Function Impairments in Patients with Depression, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612102321
DOI https://dx.doi.org/10.2174/1871527313666140612102321 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Small Neuroscience: The Nanostructure of the Central Nervous System and Emerging Nanotechnology Applications
Current Nanoscience Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry RNA Interference and Amyotrophic Lateral Sclerosis
Current Drug Metabolism Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Inherited Renal Diseases
Current Pediatric Reviews Spinal Cord Ischemia/Injury
Current Pharmaceutical Design Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives
Current Topics in Medicinal Chemistry Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology